Blog
Enavatuzumab: Revolutionizing Cancer Research Through Novel Therapeutics
Quick Facts About EnavatuzumabWhat is Enavatuzumab?Enavatuzumab is a monoclonal antibody targeting the TWEAK receptor (Fn14), pivotal in tumor growth and immune regulation.What is the me
…
17th Dec 2025
Alemtuzumab: Mechanism, Applications, and Biosimilar Advancements
Quick Facts About AlemtuzumabWhat is Alemtuzumab?Alemtuzumab is a monoclonal antibody targeting CD52, primarily used in the treatment of multiple sclerosis (MS) and certain cancers like
…
17th Dec 2025
Lemzoparlimab: Targeting CD47 for Cancer Immunotherapy Advancements
Quick Facts About LemzoparlimabWhat is Lemzoparlimab?Lemzoparlimab is a monoclonal antibody that targets CD47, a protein known for its role in helping tumors evade the immune system. By
…
6th Feb 2025
Zilovertamab: Unlocking the Potential of ROR1-Targeted Therapy
Quick Facts About ZilovertamabWhat is Zilovertamab?Zilovertamab is a monoclonal antibody targeting ROR1, a receptor tyrosine kinase overexpressed in hematologic cancers and solid tumors.
…
6th Feb 2025
Rovalpituzumab Tesirine: Advancing Small Cell Lung Cancer Research
Quick Facts About Rovalpituzumab TesirineWhat is Rovalpituzumab Tesirine?Rovalpituzumab Tesirine (Rova-T) is an antibody-drug conjugate (ADC) designed to target DLL3, a protein overexpre
…
6th Feb 2025
Ramucirumab: Mechanism, Clinical Applications, and Biosimilars in Cancer Research
Quick Facts About RamucirumabWhat is Ramucirumab?Ramucirumab is a monoclonal antibody that targets vascular endothelial growth factor receptor 2 (VEGFR-2), inhibiting angiogenesis, a pro
…
31st Jan 2025
Ponsegromab: A Breakthrough in Heart Failure and Cachexia Research
Quick Facts About PonsegromabWhat is Ponsegromab?Ponsegromab is an investigational monoclonal antibody developed by Pfizer, primarily studied for its potential in treating heart failure
…
29th Jan 2025
Patritumab Deruxtecan: Mechanism, Clinical Applications, and Biosimilar Advances
Quick Facts About Patritumab DeruxtecanWhat is Patritumab Deruxtecan?Patritumab Deruxtecan (HER3-DXd) is an investigational antibody-drug conjugate (ADC) targeting HER3, a receptor impli
…
29th Jan 2025
Ruplizumab: Unveiling the Role of Anti-CD47 in Cancer Research
Quick Facts About RuplizumabWhat is Ruplizumab?Ruplizumab is an investigational monoclonal antibody designed to target CD47, a protein that helps cancer cells evade immune detection.What
…
29th Jan 2025
Adalimumab: Mechanism, Clinical Applications, and the Role of Biosimilars
Quick Facts About AdalimumabWhat is Adalimumab?Adalimumab is a fully human monoclonal antibody designed to neutralize tumor necrosis factor-alpha (TNF-α), a key cytokine involved in infl
…
29th Jan 2025
Utomilumab: Advancing Immuno-Oncology Research
Quick Facts About UtomilumabWhat is Utomilumab?Utomilumab is a monoclonal antibody targeting 4-1BB (CD137), a co-stimulatory receptor on T-cells, designed to enhance anti-tumor immunity.
…
29th Jan 2025
Fezakinumab: Exploring Its Mechanism and Clinical Potential
Quick Facts About FezakinumabWhat is Fezakinumab?Fezakinumab is a human IgG1-lambda monoclonal antibody that targets interleukin-22 (IL-22), a cytokine involved in inflammatory responses
…
29th Jan 2025
Onvatilimab: Redefining the Role of Anti-CD47 in Cancer Research
Quick Facts About OnvatilimabWhat is Onvatilimab?Onvatilimab is a monoclonal antibody targeting CD47, often referred to as the "don't eat me" signal, which is overexpressed on many cance
…
27th Jan 2025
Siltuximab: Exploring IL-6 Inhibition in Castleman’s Disease and Research
Quick Facts About SiltuximabWhat is Siltuximab?Siltuximab is a monoclonal antibody targeting interleukin-6 (IL-6), a cytokine involved in inflammation and immune regulation.What is the m
…
16th Jan 2025
Sacituzumab: Exploring its Role in Cancer Research and the Rise of Biosimilars
Key Facts About SacituzumabWhat is Sacituzumab?Sacituzumab is an antibody-drug conjugate (ADC) that targets the tumor-associated antigen Trop-2, used to treat various cancers, including
…
16th Jan 2025
Brentuximab: Unveiling the Role of Anti-CD30 in Cancer Research
Key Facts About BrentuximabWhat is Brentuximab?Brentuximab is a monoclonal antibody targeting CD30, commonly used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell
…
15th Jan 2025
Gemtuzumab: Advancing CD33-Targeted Therapies in AML Research
Key Facts About GemtuzumabWhat is Gemtuzumab?Gemtuzumab is an antibody-drug conjugate (ADC) targeting CD33, a protein expressed on the surface of myeloid cells. It is widely recognized f
…
15th Jan 2025
Indatuximab: Advancing CD138-Targeted Therapy in Cancer Research
What You Need to Know About IndatuximabWhat is Indatuximab?Indatuximab ravtansine is an experimental monoclonal antibody-drug conjugate (ADC) that targets CD138, a protein highly express
…
14th Jan 2025
Pinatuzumab: Advancing Cancer Research and Therapeutics
Quick Facts About PinatuzumabWhat is Pinatuzumab?Pinatuzumab is an antibody-drug conjugate (ADC) designed to target CD22, a protein highly expressed on B-cell malignancies, including non
…
12th Dec 2024
Belantamab: A Game-Changer in Multiple Myeloma Therapy
Quick Facts About BelantamabWhat is Belantamab?Belantamab Mafodotin is a cutting-edge antibody-drug conjugate (ADC) designed for the treatment of relapsed or refractory multiple myeloma.
…
12th Dec 2024
Girentuximab: Exploring Its Mechanism, Clinical Potential, and Research Advancements
Quick Facts About GirentuximabWhat is Girentuximab?Girentuximab is a monoclonal antibody targeting carbonic anhydrase IX (CAIX), predominantly expressed in renal cell carcinoma (RCC) cel
…
10th Dec 2024